Summary The camptothecins are a new class of chemotherapeutic agents which have a novel mechanism of action targeting the nuclear enzyme topoisomerase I. Knowledge of the structure-activity relationships of the parent compound camptothecin has led to the development of effective soluble analogues with manageable toxicities. Broad anti-tumour activity shown in preclinical studies has been confirmed in phase I/II studies for irinotecan and topotecan. Two other derivatives, 9-aminocamptothecin and GI 14721 IC, are undergoing phase I and early phase II evaluation. Although camptothecin is a plant extract, it and most of its derivatives are not affected by the classic p_gpMDRI mechanism of resistance which may allow the development of novel combination chemotherapeutic regimens. Important areas of future endeavour will include the development of rational combination regimens and the pursuit of randomised trials. Based on single agent data, colorectal cancer and non-small-cell lung cancer should be the focus for future irinotecan studies. Small-cell lung cancer and ovarian carcinoma are logical tumour types to pursue with topotecan. Both 9-aminocamptothecin and GI 14721 IC are too early in their clinical evaluation to make recommendations about their future roles. Finally, the unfolding story of camptothecin analogue development will give important insights into the predictive value of preclinical observations on relative efficacy, schedule dependency, combination strategies and resistance mechanisms which have helped determine the strategies for clinical evaluation of these agents.
More than 30 years ago, an extract from the Chinese tree Camptotheca acuminata was found to have anti-tumour activity in experimental systems (Wall et al., 1966) . The active compound, camptothecin, being insoluble in aqueous solution, was modified and its water-soluble sodium salt was evaluated in clinical studies in the late 1960s and early 1970s. Leucopenia and thrombocytopenia were dose-limiting toxicities (Muggia et al., 1972) . Despite promising anti-tumour activity in phase I studies, results in phase II trials in patients with gastrointestinal malignancies (Moertel et al., 1972) and melanoma (Gottlieb, 1972) indicated the drug was ineffective and highly toxic. Myelosuppression, vomiting, diarrhoea and sterile haemorrhagic cystitis were often severe and, as a result, further clinical testing of camptothecin ceased. Several developments in the late 1980s renewed interest in camptothecin: topoisomerase I was identified as the cellular target of the drug (Hsiang et al., 1988) ; the structure-activity relationship was determined for camptothecin (Jaxel et al., 1989) , leading to the development of effective, water-soluble synthetic and semisynthetic derivatives (Wall et al., 1993) ; and topoisomerase I levels were found to be higher in some tumour tissues compared with the normal tissue counterpart (Giovanella et al., 1989 ; Van der Zee et al., 1991) . Currently camptothecin and four analogues: topotecan, irinotecan (CPT-l1), 9-aminocamptothecin and GI 147211C (GG211) are undergoing clinical evaluation. During the past 25 years, knowledge of topoisomerase biochemistry, genetics, molecular biology and interaction with inhibitors has increased exponentially and these will be reviewed with the results of preclinical and clinical evaluations of camptothecin and its derivatives.
DNA topoisomerase I
Topoisomerases are nuclear enzymes that modulate the threedimensional structure of DNA by inducing transient breaks that allow unwinding of supercoiled DNA (reviewed in Pommier, 1993) . Topoisomerase I is a 100 000 kDa protein
Correspondence: E Eisenhauer Received 27 February, 1996 which relaxes positive and negative supercoils of DNA arising during DNA and RNA synthesis by making transient single-stranded breaks in DNA (Champoux, 1976) . Intense research has clarified the camptothecin -topoisomerase I-DNA interaction. The drug binds to and stabilises the topoisomerase I enzyme -DNA cleavable complex after DNA cleavage preventing resealing of DNA and causing an accumulation of cleavable complexes (Hsiang et al., 1988 (Hsiang et al., , 1989 . The subsequent interaction between the advancing replication fork of DNA and the drug-stabilised cleavable complex results in an arrest of DNA replication with formation of double-strand breaks. These in turn activate endonucleases, triggering further DNA fragmentation and ultimately cell death (Zhang et al., 1990) . Thus, cytotoxicity is dependent on the expression of topoisomerase I and on DNA replication. Compared with the levels of the enzyme in normal tissues, a significant increase of topoisomerase I has been detected in surgical specimens of colon adenocarcinoma, ovarian and oesophageal carcinoma, in cultures of nonHodgkin's lymphoma and leukaemia cells and in xenograft lines of human colon adenocarcinoma, carcinoma of the stomach, breast, lung and malignant melanoma (Potmesil, 1994) . Cell lines which have high levels of enzyme are hypersensitive to camptothecin-induced cytotoxicity (Madden, 1992) . Conversely, cell lines resistant to camptothecin may contain qualitatively or quantitatively altered forms of the target enzyme (Pommier, 1993) . Although topoisomerase I is expressed throughout the cell cycle, cells in S-phase are 1000 times more sensitive than cells in G, or G2-phase to the cytotoxicity of camptothecins reflecting the need for DNA replication for drug efficacy (Del Bino et al., 1991) . Although much is known, our understanding of the mechanism of activity of these agents might be incomplete. These agents are active in human tumour xenografts that typically have low Sphase fractions and studies have shown that the fraction of cells killed by a brief exposure to camptothecin is sometimes larger than the S-phase fraction of the cell population, thus other cellular effects of camptothecins may be linked to cytotoxicity (O'Connor et al., 1991) .
Structure -activity experiments have defined the features of the molecule critical for cytotoxicity. Camptothecin has a heterocyclic five-ring structure with a lactone moiety and an S-hydroxyl moiety on ring E (Figure 1 (Hertzberg et al., 1989a,b) . Substitutions at positions 9 or 10 by amino or hydroxyl groups lead to compounds with equal or greater in vivo activity than the parent compound (Wani et al., 1980 (Wani et al., , 1987 . Knowledge of these features has led to the development of analogues of camptothecin which are both water soluble and effective. Four analogues are now undergoing clinical evaluation: irinotecan, topotecan, 9-aminocamptothecin and GI 147211 (GG21 1). Irinotecan (CPT-ll) Preclinical studies The first of the water-soluble analogues is irinotecan (CPT-11) or 7-ethyl-10-(4-[1-piperidino]-l-piperidino)methyl-10-hydroxycamptothecin. Irinotecan, a prodrug with limited activity, is converted in plasma by de-esterification into SN-38 which has 1000 times the potency of the parent compound (Kawato et al., 1991a) .
Irinotecan is active against a diverse array of tumour cell lines in vitro and in vivo. The metabolite is a more effective inhibitor of topoisomerase I and more cytotoxic toward human colon carcinoma cells in culture than camptothecin, 9-aminocamptothecin and topotecan (Tanizawa et al., 1994) . Irinotecan, when given by intraperitoneal, intravenous or oral routes, showed substantial activity against a broad spectrum of mouse and human tumour xenografts including human cancer xenograft lines resistant to topotecan, vincristine or melphalan (Kunimoto et al., 1987) . Interestingly, sensitivities of some tumour cell lines to irinotecan were independent of their ability to produce SN-38 suggesting that cytotoxicity is not solely dependent on the
-OCH2CH20-production of the metabolite (Kawato et al., 1991b) . Unlike 9-aminocamptothecin and topotecan, the efficacy of irinotecan was not substantially influenced by administration schedule in preclinical studies (Furuta, 1990) .
Clinical studies of irinotecan Clinical evaluation of irinotecan is well advanced. Phase I trials (Table I) (Rowinsky et al., 1994a) . Peak plasma levels and AUC of irinotecan correlate well with dose (De Forni et al., 1994) . The AUC of SN-38 correlates with the AUC but not the dose of irinotecan. The reported terminal half-life of irinotecan is 5.2-9.3 h, and the mean residence times for it and SN-38 are 9.1 and 10.0 h. Hydrolysis of irinotecan and SN-38 lactone is less than for topotecan and 9-aminocamptothecin with 33-66% remaining intact at 24 h after infusion of irinotecan. The maintenance of biologically relevant concentrations of SN-38 for long durations may explain the observation that anti-tumour efficacy of irinotecan is not schedule dependent. There is significant interpatient variability in the conversion of irinotecan to SN-38, implying that dose increases may not lead to proportional increases in cytotoxicity.
Biliary and urinary excretion are both important routes of elimination. In humans 37+4% of the drug is detected in urine in 48 h (Rowinsky, 1994a) . Both irinotecan and SN-38 undergo glucuronic acid conjugation and are eliminated in bile (Narita et al., 1993; . fl-Glucuronidase of intestinal microflora can cleave the glucuronide and free intestinal SN-38 which may play a role in producing the late diarrhoea. Indirect estimates of biliary concentration of SN-38 and its glucuronide have shown good correlation between the concentration of SN-38 and the occurrence of late diarrhoea (Araki et al., 1993) .
In single agent phase II trials (Table II) , irinotecan was active against a wide range of carcinomas and lymphomas. Activity was observed using schedules of 100-150mg m-2 week-1 and 350 mg m-2 every 3 weeks. The response rates appear to favour weekly administration but direct comparisons between the two schedules have not been made. Of particular interest are the results of five trials in patients with metastatic colorectal cancer where response rates have ranged from 14% to 32%. Similar levels of activity have been seen in untreated colorectal patients, patients previously treated with 5-FU and patients who were treated after progressing on 5-FU (Bugat et al., 1995) . Response rates of 34% and 36% were observed in untreated patients with non-small-cell lung cancer. Complete and partial remissions were seen in 24% of ovarian cancer and 23% of breast cancer patients who had received prior chemotherapy. Results of three studies in patients with cervical cancer have been mixed, perhaps reflecting different schedules and patient populations. On the weekly schedule response rates of 24-27% were observed in patients previously treated with cisplatin but 0% in patients who were refractory to cisplatin. A response rate of 15% was observed in chemotherapy-naive patients on the 3 weekly schedule but 24% in the subset of 21 patients who had measurable disease outside previously irradiated fields. Partial responses were seen in 23% of patients with advanced gastric cancer, 40% of patients with small-cell lung cancer and in 39% with non-Hodgkin's lymphoma. Thus, irinotecan has impressive activity in many malignancies particularly colorectal carcinoma, non-small-cell lung cancer and cervical carcinoma. Toxic effects are usually manageable but late diarrhoea may be severe despite maximal medical therapy. Because of this it may be challenging to combine this drug with other cytotoxic agents particularly those with similar toxicities. A direct comparison of the weekly and 3 weekly schedule is an obvious question to be addressed in a comparative trial.
Future directions Future study of irinotecan will be likely to fall into three major areas: the pursuit of effective (preferably mechanismbased) methods of overcoming the late diarrhoea, the development of rational, safe combination regimens (see section on Combination treatment) and the randomised comparison of irinotecan-based regimens with standard therapy. The tumour types which ought to be the focus of the initial group of comparative trials include both colorectal cancer and non-small-cell lung cancer based on the single agent data in these diseases.
Secondary areas of endeavour which merit evaluation include further phase II testing, particularly in those tumour types with supportive preclinical data such as sarcoma and glioma, and the development of a better understanding of the pharmacokinetic/dynamic relationship of the drug to toxic and efficacy outcomes.
Topotecan
Preclinical studies Topotecan (9-(dimethylamino)methyl-10-hydroxycamptothecin) is a camptothecin derivative having aqueous solubility conferred by the charged amino group on the 9-substituent. When tested against a variety of transplantable mouse and human tumours, topotecan demonstrated anti-tumour (Grochow et al., 1994 Although the dose-limiting toxicity of topotecan was neutropenia, attempts to improve dose intensity on the daily x 5 schedule by using haematopoietic growth factors were not successful (Murphy et al., 1992; Rowinsky et al., 1992; Janik et al., 1993) .
Since several anti-tumour responses were seen in the daily x 5 phase I trial, this schedule was selected for phase II evaluation. Following this decision, the 21-day c.i.v. phase I trial was completed and also appeared active, thus a limited number of phase II trials have been initiated with the more prolonged schedule.
Because of its broad activity in phase I studies, phase II studies of topotecan were initiated for many different tumour types (Table IV) . In a randomised phase II study comparing the daily x 5 day schedule to 72 h c.i.v. schedule in untreated patients with advanced NSCLC, response rate, median time to progression and median survival favoured the daily for 5 days schedule (Weitz et al., 1995) . In untreated colorectal cancer an 8% response rate was seen using the 21-day c.i.v. schedule. This response rate was similar to that observed in colorectal carcinoma with the daily x 5 day schedule, but the c.i.v. administration was associated with significant cumulative myelosuppression and pronounced anaemia (Creemer et al., 1995) . Activity in other tumour types on the daily x 5 schedule included response rates of 40% and 21% in untreated and previously treated SCLC respectively, 33% in breast cancer and 27% in head and neck cancer. In two trials involving heavily pretreated patients 
9-Aminocamptothecin
Among the many semisynthetic or totally synthetic camptothecin analogues screened, 9-aminocamptothecin was selected for advanced testing and clinical development primarily because of its ability to induce complete remissions in mice bearing human colonic adenocarcinoma and malignant melanoma cell lines known to be resistant to standard chemotherapeutic agents (Giovanella et al., 1989 (Giovanella et al., , 1991 Pantazis et al., 1992) . Like topotecan, pharmacokinetic and efficacy studies of 9-aminocamptothecin suggested that maintaining the lactone plasma concentration above a threshold level for a prolonged period was required for optimal therapeutic effect (Supko et al., 1993 (Dahut et al., 1994) . Preliminary pharmacokinetic studies of 9-aminocamptothecin given as a 72 h infusion were done as part of the phase I evaluation (Takimoto et al., 1994) . Steady-state plasma concentrations increased linearly from 0.89+0.63 nM to 5.6 +0.6 nM over the dose range of 5 to 59 jg m-2 h-' and total body clearance was 26.5 + 8.6 ml min m-2. Nonlinear regression analysis demonstrated biphasic pharmacokinetics for 9-aminocamptothecin lactone with a t1/2, of 1.5-2.5 h and a t1/2, of 10.7-12.9 h. Mean steady-state plasma levels of 9-aminocamptothecin lactone correlated well with the percentage decrease in granulocyte and leucocyte counts. Phase II testing of 9-aminocamptothecin as a 72 h infusion every 2 weeks is ongoing. Furthermore, clinical testing of a colloid dispersion formulation which improves the aqueous solubility of 9-aminocamptothecin 20-fold is under way. (Bertrand et al., 1992; Kaufmann, 1991 (Kim et al., 1992) . In a phase I study of topotecan given by continuous infusion on days 1-3 and etoposide given over 2 h on days 7-9, sequential sampling of tumours in five patients was performed. Topoisomerase II levels were markedly increased immediately before etoposide was given on day 7 and levels decreased by day 9 in the tumour cells of one patient who had resolution of malignant ascites (Eckardt et al., 1994 (Andoh et al., 1987; Tanizawa et al., 1993) . Point mutations (Benedetti et al., 1993) , deletions (Sugimoto et al., 1990b) and rearrangements (Tan et al., 1989) Two other potentially important mechanisms of resistance have been described. Reduced conversion of the prodrug irinotecan to its active metabolite SN-38 caused loss of efficacy in a cell line selected for resistance to camptothecins (Niimi et al., 1992) . Finally, molecular inhibitors of apoptosis such as overexpression of bcl-2 decreased cytotoxicity of camptothecins (Walton et al., 1993) . The clinical relevance of all of these mechanisms of resistance remains to be established.
Discussion
Topoisomerase I inhibitors represent a promising new class of chemotherapeutic agents with a novel mechanism of action. Renewed interest in their study after the initial failure of the parent compound in clinical trials 20 years ago has been driven not only by the understanding of their mechanism of action, but also by an appreciation of structure -activity relationships. The broad anti-tumour activity shown in cell culture and animal studies has been confirmed in clinical phase I/II evaluation of irinotecan and topotecan.
Irinotecan has activity in an array of solid tumours but because of the impressive results in NSCLC and colorectal carcinoma these two tumour types should be the primary focus for the development of combination therapy and randomised trials, at least initially. Preclinical studies have provided helpful information for the development of combination regimens and favour sequential administration of irinotecan with DNA-damaging agents such as cisplatin and topoisomerase II inhibitors such as etoposide. Irinotecan and 5-FU in colorectal carcinoma are also an obvious combination for evaluation and clinical studies are ongoing. In terms of drug delivery, both the weekly and 3-weekly schedules have been shown to be effective; which of the two provides the best therapeutic index is also a question for comparative trials. In addition to the goal of improving efficacy in these and other tumour types, attention must be paid to the toxic effects, especially diarrhoea. Despite maximal therapy diarrhoea remains problematic and will need new solutions before irinotecan can be easily assimilated into routine practice.
Topotecan has a much more favourable toxicity profile than irinotecan but its spectrum of activity in phase II trials is somewhat less impressive. Clearly further studies of topotecan in combination with other effective cytotoxic agents are warranted in SCLC, head and neck cancer, ovarian cancer and possibly breast cancer. Its activity in previously treated ovarian cancer is of particular interest. The results of the recently completed phase III trial comparing the efficacy of topotecan with paclitaxel will be important in determining the enthusiasm for incorporating topotecan into front-line ovarian cancer regimens. In SCLC, the role of topotecan in first-line treatment should be explored and a study addressing this question is currently ongoing in the United States. Phase I/II studies are also underway with topotecan in combination with alkylating agents and topoisomerase II inhibitors similar to those described for irinotecan. At the present time the daily for 5 days schedule appears to offer the best balance of efficacy and toxicity compared with 72 h or 21 day c.i.v. schedules, despite preclinical data favouring prolonged drug exposure. However, clinical studies examining the question of prolonged administration have been limited to tumour sites in which topotecan has not shown impressive activity on the daily x 5 day schedule so these may not have been good models in which to study alternative schedules.
There is no doubt that the clinical data have confirmed that the camptothecins represent an exciting new class of chemotherapeutic agents. The role each analogue will play in improving survival or palliative treatment of specific malignancies is evolving with the present generation of randomised trials but this will take several years to unfold. The data on topotecan and irinotecan have shown how modifications of the parent molecule lead to substantially different efficacy and toxicity profiles. Thus, results of phase II studies with 9-aminocamptothecin and GG 211 will be of great interest.
An additional aspect of the story of camptothecin development deserves comment. It is to point out the critical role that preclinical experiments played in resurrecting the interest in a class of compounds that would otherwise have remained abandoned. The identification of a unique mechanism of action and the chemical studies to determine structure -activity relationships permitted the synthesis of new molecules which were appropriate for clinical evaluation. Furthermore, the clinical trials themselves have been shaped to accommodate new schedules or end points, such as critical blood levels, when preclinical data suggested these factors might play an important role in efficacy. It will be of interest to see if these predictions prove to be accurate as clinical experience matures. Meanwhile the preclinical -clinical dialogue must continue to further our understanding of the determinants of toxicity, resistance and efficacy. Such data will allow optimisation of the use of these agents and permit the development of better analogues in this class.
